Ingredient Spotlight: ForsLEAN

Coleus forskohlii, a plant native to subtropical and warm temperate habitats has been used since ancient times as a medicinal herb in India. Also known as Kaffir Potatoes, coleus forskohlii has several ethnomedicinal uses. According to Ayurveda, this mint-like anti-inflammatory herb has been used to ease pain, support healthy inflammation response, to help manage skin-related problems, ascites (fluid retention), external ulcers, abdominal pain, low appetite, urine retention and constipation. It’s only within the last 40 years that coleus forskohlii has captured the attention of medical researchers for much broader pharmacological benefits.

Checkout these published studies of ForsLEAN®, a patented form of coleus forskohlii:


In an 8-week, open-field, pilot study, effect of ForsLEAN® on weight loss and lean body mass was tested in obese women volunteers. Each participant was advised to take 2 capsules containing 250 mg of the standardized extract (i.e., 10% forskolin) twice daily, and were examined by a physician at the inception and after 4 and 8 weeks of the study.
Participants were asked to maintain their previous daily physical exercise and eating habits. Results suggested that upon supplementation, mean values for body weight and fat content were significantly decreased (p<0.05 both), whereas lean body mass was significantly increased (p<0.05) as compared to the baseline. In conclusion, ForsLEAN® supplementation was found to be a safe and effective weight loss regimen.




Another well supporting clinical trial reported that a dose of 250 mg of ForsLEAN® twice daily, significantly increased lean body mass and decreased body fat in obese male subjects. This randomized, double-blind, placebo-controlled 12 weeks study evaluated the effect of forskolin on body composition, testosterone, metabolic rate and blood pressure in 30 overweight and obese men.

ForsLEAN® supplementation elicited favorable changes in body composition by significantly decreasing body fat percentage and fat mass compared with the placebo group (p≤0.05). Additionally, forskolin administration resulted in an increase in bone mass compared with the placebo group (p≤0.05). There was a trend toward a significant increase for lean body mass in the forskolin group compared with placebo (p≤0.097).



Effective mitigation of gains in body mass (p=0.10) and scanned mass (p=0.08) was witnessed when 23 overweight female volunteers were supplemented with ForsLEAN® in a 12-week, double-blind, randomized clinical trial. Overall, results suggested that ForsLEAN® may help mitigate weight gain in overweight females with apparently no clinically significant side effects.


Leave a comment

Please note, comments must be approved before they are published